Therapeutic oligonucleotides targeting liver disease: TTR amyloidosis

Molecules

Volumn 20, Issue 10, 2015, Pages 17944-17975

  Niemietz, Christoph ^a   Chandhok, Gursimran ^a   Schmidt, Hartmut ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antisense oligonucleotide; Familial amyloid polyneuropathy; Liver; Small interfering RNA; Transthyretin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; PREALBUMIN; SMALL INTERFERING RNA;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMAL; CHEMISTRY; CLINICAL STUDY; GENE SILENCING; GENE THERAPY; GENETICS; HUMAN; LIVER DISEASES; MUTATION; PRECLINICAL STUDY; RNA INTERFERENCE; TREATMENT OUTCOME;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; CLINICAL STUDIES AS TOPIC; DRUG EVALUATION, PRECLINICAL; GENE SILENCING; GENETIC THERAPY; HUMANS; LIVER DISEASES; MUTATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PREALBUMIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84947600601     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules201017944     Document Type: Review

References (181)

1. Zamecnik, P.C.; Stephenson, M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 1978, 75, 280-284.
2. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
3. Goodchild, J. Therapeutic oligonucleotides. Methods Mol. Biol. 2011, 764, 1-15.
4. Taft, R.J.; Pang, K.C.; Mercer, T.R.; Dinger, M.; Mattick, J.S. Non-coding RNAs: Regulators of disease. J. Pathol. 2010, 220, 126-139.
5. Hrdlickova, B.; de Almeida, R.C.; Borek, Z.; Withoff, S. Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease. Biochim. Biophys. Acta 2014, 1842, 1910-1922.
6. Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11, 125-140.
7. Perez, B.; Vilageliu, L.; Grinberg, D.; Desviat, L.R. Antisense mediated splicing modulation for inherited metabolic diseases: Challenges for delivery. Nucleic Acid Ther. 2014, 24, 48-56.
8. Fatemi, R.P.; Velmeshev, D.; Faghihi, M.A. De-repressing LncRNA-Targeted Genes to Upregulate Gene Expression: Focus on Small Molecule Therapeutics. Mol. Ther. Nucleic Acids 2014, 3, e196, doi: 10.1038/mtna.2014.45.
9. Modarresi, F.; Faghihi, M.A.; Lopez-Toledano, M.A.; Fatemi, R.P.; Magistri, M.; Brothers, S.P.; van der Brug, M.P.; Wahlestedt, C. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 2012, 30, 453-459.
10. Lorenzer, C.; Dirin, M.; Winkler, A.M.; Baumann, V.; Winkler, J. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 2015, 203, 1-15.
11. Sehgal, A.; Vaishnaw, A.; Fitzgerald, K. Liver as a target for oligonucleotide therapeutics. J. Hepatol. 2013, 59, 1354-1359.
12. Davidson, B.L.; McCray, P.B., Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12, 329-340.
13. Lee, R.G.; Crosby, J.; Baker, B.F.; Graham, M.J.; Crooke, R.M. Antisense technology: An emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 2013, 6, 969-980.
14. Krieg, A.M. Is RNAi dead? Mol. Ther. 2011, 19, 1001-1002.
15. Santos, R.D.; Raal, F.J.; Donovan, J.M.; Cromwell, W.C. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J. Clin. Lipidol. 2015, 9, 201-209.
16. Karlsen, T.H.; Lammert, F.; Thompson, R.J. Genetics of liver disease: From pathophysiology to clinical practice. J. Hepatol. 2015, 62, S6-S14.
17. Plante-Bordeneuve, V.; Kerschen, P. Transthyretin familial amyloid polyneuropathy. Handb. Clin. Neurol. 2013, 115, 643-658.
18. Andrade, C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952, 75, 408-427.
19. Costa, P.P.; Figueira, A.S.; Bravo, F.R. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc. Natl. Acad. Sci. USA 1978, 75, 4499-4503.
20. Saraiva, M.J.; Costa, P.P.; Birken, S.; Goodman, D.S. Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Trans. Assoc. Am. Physicians 1983, 96, 261-270.
21. Holmgren, G.; Costa, P.M.; Andersson, C.; Asplund, K.; Steen, L.; Beckman, L.; Nylander, P.O.; Teixeira, A.; Saraiva, M.J.; Costa, P.P. Geographical distribution of TTR met30 carriers in northern Sweden: Discrepancy between carrier frequency and prevalence rate. J. Med. Genet. 1994, 31, 351-354.
22. Araki, S.; Ando, Y. Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010). Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2010, 86, 694-706.
23. Sousa, A.; Andersson, R.; Drugge, U.; Holmgren, G.; Sandgren, O. Familial amyloidotic polyneuropathy in Sweden: Geographical distribution, age of onset, and prevalence. Hum. Hered. 1993, 43, 288-294.
24. Benson, M.D.; Kincaid, J.C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007, 36, 411-423.
25. Spiekerman, A.M. Nutritional assessment (protein nutriture). Anal. Chem. 1995, 67, 429R-436R.
26. Episkopou, V.; Maeda, S.; Nishiguchi, S.; Shimada, K.; Gaitanaris, G.A.; Gottesman, M.E.; Robertson, E.J. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc. Natl. Acad. Sci. USA 1993, 90, 2375-2379.
27. Palha, J.A.; Hays, M.T.; Morreale de Escobar, G.; Episkopou, V.; Gottesman, M.E.; Saraiva, M.J. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am. J. Physiol. 1997, 272, E485-E493.
28. Saraiva, M.J. Transthyretin amyloidosis: A tale of weak interactions. FEBS Lett. 2001, 498, 201-203.
29. Merlini, G.; Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 2003, 349, 583-596.
30. Ferrao-Gonzales, A.D.; Souto, S.O.; Silva, J.L.; Foguel, D. The preaggregated state of an amyloidogenic protein: Hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc. Natl. Acad. Sci. USA 2000, 97, 6445-6550.
31. Gorevic, P.D.; Prelli, F.C.; Wright, J.; Pras, M.; Frangione, B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: Immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J. Clin. Investig. 1989, 83, 836-843.
32. Quarta, C.C.; Guidalotti, P.L.; Longhi, S.; Pettinato, C.; Leone, O.; Ferlini, A.; Biagini, E.; Grigioni, F.; Bacchi-Reggiani, M.L.; Lorenzini, M.; et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc. Imaging 2012, 5, 755-758.
33. Jacobson, D.R.; Gorevic, P.D.; Buxbaum, J.N. A homozygous transthyretin variant associated with senile systemic amyloidosis: Evidence for a late-onset disease of genetic etiology. Am. J. Hum. Genet. 1990, 47, 127-136.
34. Tanskanen, M.; Peuralinna, T.; Polvikoski, T.; Notkola, I.L.; Sulkava, R.; Hardy, J.; Singleton, A.; Kiuru-Enari, S.; Paetau, A.; Tienari, P.J.; et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in a2-macroglobulin and tau: A population-based autopsy study. Ann. Med. 2008, 40, 232-239.
35. Jacobson, D.R.; Pastore, R.; Pool, S.; Malendowicz, S.; Kane, I.; Shivji, A.; Embury, S.H.; Ballas, S.K.; Buxbaum, J.N. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum. Genet. 1996, 98, 236-238.
36. Ranlov, I.; Alves, I.L.; Ranlov, P.J.; Husby, G.; Costa, P.P.; Saraiva, M.J. A Danish kindred with familial amyloid cardiomyopathy revisited: Identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am. J. Med. 1992, 93, 3-8.
37. Zeldenrust, S.R. Genotype-phenotype correlation in FAP. Amyloid 2012, 19 (Suppl. S1), 22-24.
38. Ando, Y.; Coelho, T.; Berk, J.L.; Cruz, M.W.; Ericzon, B.G.; Ikeda, S.; Lewis, W.D.; Obici, L.; Plante-Bordeneuve, V.; Rapezzi, C.; et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J. Rare Dis. 2013, 8, 31, doi: 10.1186/1750-1172-8-31.
39. Seca, M.; Ferreira, N.; Coelho, T. Vitreous amyloidosis as the presenting symptom of familial amyloid polyneuropathy TTR Val30Met in a portuguese patient. Case Rep. Ophthalmol. 2014, 5, 92-97.
40. Rapezzi, C.; Quarta, C.C.; Riva, L.; Longhi, S.; Gallelli, I.; Lorenzini, M.; Ciliberti, P.; Biagini, E.; Salvi, F.; Branzi, A. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat. Rev. Cardiol. 2010, 7, 398-408.
41. Schmidt, H.H.; Nashan, B.; Propsting, M.J.; Nakazato, M.; Flemming, P.; Kubicka, S.; Boker, K.; Pichlmayr, R.; Manns, M.P. Familial Amyloidotic Polyneuropathy: Domino liver transplantation. J. Hepatol. 1999, 30, 293-298.
42. Ando, Y.; Tanaka, Y.; Nakazato, M.; Ericzon, B.G.; Yamashita, T.; Tashima, K.; Sakashita, N.; Suga, M.; Uchino, M.; Ando, M. Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem. Biophys. Res. Commun. 1995, 211, 354-358.
43. Okamoto, S.; Wixner, J.; Obayashi, K.; Ando, Y.; Ericzon, B.G.; Friman, S.; Uchino, M.; Suhr, O.B. Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival. Liver Transpl. 2009, 15, 1229-1235.
44. Terazaki, H.; Ando, Y.; Nakamura, M.; Obayashi, K.; Misumi, S.; Shoji, S.; Yamashita, S.; Nakagawa, K.; Ishizaki, T.; Suhr, O.; et al. Variant transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: Qualitative analyses of transthyretin metabolism in sequential liver transplantation. Transplantation 2001, 72, 296-299.
45. Ruberg, F.L.; Berk, J.L. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012, 126, 1286-1300.
46. Yazaki, M.; Mitsuhashi, S.; Tokuda, T.; Kametani, F.; Takei, Y.I.; Koyama, J.; Kawamorita, A.; Kanno, H.; Ikeda, S.I. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am. J. Transplant. 2007, 7, 235-242.
47. Suhr, O.B.; Friman, S.; Ericzon, B.G. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005, 12, 233-238.
48. Almeida, M.R.; Macedo, B.; Cardoso, I.; Alves, I.; Valencia, G.; Arsequell, G.; Planas, A.; Saraiva, M.J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 2004, 381, 351-356.
49. Coelho, T.; Maurer, M.S.; Suhr, O.B. THAOS-The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr. Med. Res. Opin. 2013, 29, 63-76.
50. Berk, J.L.; Suhr, O.B.; Obici, L.; Sekijima, Y.; Zeldenrust, S.R.; Yamashita, T.; Heneghan, M.A.; Gorevic, P.D.; Litchy, W.J.; Wiesman, J.F.; et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. JAMA 2013, 310, 2658-2667.
51. Coelho, T.; Maia, L.F.; Martins da Silva, A.; Waddington Cruz, M.; Plante-Bordeneuve, V.; Lozeron, P.; Suhr, O.B.; Campistol, J.M.; Conceicao, I.M.; Schmidt, H.H.; et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012, 79, 785-792.
52. Merlini, G.; Plante-Bordeneuve, V.; Judge, D.P.; Schmidt, H.; Obici, L.; Perlini, S.; Packman, J.; Tripp, T.; Grogan, D.R. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J. Cardiovasc. Transl. Res. 2013, 6, 1011-1020.
53. Coelho, T.; Maia, L.F.; da Silva, A.M.; Cruz, M.W.; Plante-Bordeneuve, V.; Suhr, O.B.; Conceicao, I.; Schmidt, H.H.; Trigo, P.; Kelly, J.W.; et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J. Neurol. 2013, 260, 2802-2814.
54. Propsting, M.J.; Blaschke, M.; Haas, R.E.; Genschel, J.; Hedrich, H.J.; Manns, M.P.; Schmidt, H.H. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem. Biophys. Res. Commun. 1999, 260, 313-317.
55. Propsting, M.J.; Kubicka, S.; Genschel, J.; Manns, M.P.; Lochs, H.; Schmidt, H.H. Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture. Biochem. Biophys. Res. Commun. 2000, 279, 970-973.
56. Stephenson, M.L.; Zamecnik, P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 1978, 75, 285-288.
57. Bennett, C.F.; Swayze, E.E. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 259-293.
58. Baker, B.F.; Lot, S.S.; Condon, T.P.; Cheng-Flournoy, S.; Lesnik, E.A.; Sasmor, H.M.; Bennett, C.F. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 1997, 272, 11994-12000.
59. Mercatante, D.R.; Kole, R. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. Biochim. Biophys. Acta 2002, 1587, 126-132.
60. Cazenave, C.; Frank, P.; Toulme, J.J.; Busen, W. Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes. J. Biol. Chem. 1994, 269, 25185-25192.
61. Shoeman, R.L.; Hartig, R.; Huang, Y.; Grub, S.; Traub, P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 1997, 7, 291-308.
62. Forsha, S.J.; Panyutin, I.V.; Neumann, R.D.; Panyutin, I.G. Intracellular traffic of oligodeoxynucleotides in and out of the nucleus: Effect of exportins and DNA structure. Oligonucleotides 2010, 20, 277-284.
63. Hu, Q.; Bally, M.B.; Madden, T.D. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res. 2002, 30, 3632-3641.
64. Hartig, R.; Shoeman, R.L.; Janetzko, A.; Grub, S.; Traub, P. Active nuclear import of single-stranded oligonucleotides and their complexes with non-karyophilic macromolecules. Biol. Cell 1998, 90, 407-426.
65. Cerritelli, S.M.; Crouch, R.J. Ribonuclease H: The enzymes in eukaryotes. FEBS J. 2009, 276, 1494-1505.
66. Nakamura, H.; Oda, Y.; Iwai, S.; Inoue, H.; Ohtsuka, E.; Kanaya, S.; Kimura, S.; Katsuda, C.; Katayanagi, K.; Morikawa, K.; et al. How does RNase H recognize a DNA.RNA hybrid? Proc. Natl. Acad. Sci. USA 1991, 88, 11535-11539.
67. Pallan, P.S.; Egli, M. Insights into RNA/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex. Cell Cycle 2008, 7, 2562-2569.
68. Wu, H.; Lima, W.F.; Crooke, S.T. Properties of cloned and expressed human RNase H1. J. Biol. Chem. 1999, 274, 28270-28278.
69. Yamamoto, T.; Fujii, N.; Yasuhara, H.; Wada, S.; Wada, F.; Shigesada, N.; Harada-Shiba, M.; Obika, S. Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice. Nucleic Acid Ther. 2014, 24, 283-290.
70. Mou, T.C.; Gray, D.M. The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications. Nucleic Acids Res. 2002, 30, 749-758.
71. Brown, D.A.; Kang, S.H.; Gryaznov, S.M.; DeDionisio, L.; Heidenreich, O.; Sullivan, S.; Xu, X.; Nerenberg, M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 1994, 269, 26801-26805.
72. Lorenz, P.; Baker, B.F.; Bennett, C.F.; Spector, D.L. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell 1998, 9, 1007-1023.
73. Geary, R.S.; Yu, R.Z.; Levin, A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2001, 2, 562-573.
74. Clark, C.L.; Cecil, P.K.; Singh, D.; Gray, D.M. CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12 [d/r(GT/U)]12 and the influence of phosphorothioate substitution. Nucleic Acids Res. 1997, 25, 4098-4105.
75. Warfield, K.L.; Panchal, R.G.; Aman, M.J.; Bavari, S. Antisense treatments for biothreat agents. Curr. Opin. Mol. Ther. 2006, 8, 93-103.
76. Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270, 1628-1644.
77. Geary, R.S.; Khatsenko, O.; Bunker, K.; Crooke, R.; Moore, M.; Burckin, T.; Truong, L.; Sasmor, H.; Levin, A.A. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 2001, 296, 898-904.
78. Goemans, N.M.; Tulinius, M.; van den Akker, J.T.; Burm, B.E.; Ekhart, P.F.; Heuvelmans, N.; Holling, T.; Janson, A.A.; Platenburg, G.J.; Sipkens, J.A.; et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 2011, 364, 1513-1522.
79. Furdon, P.J.; Dominski, Z.; Kole, R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 1989, 17, 9193-9204.
80. Berezney, J.P.; Saleh, O.A. Locked nucleic acid oligomers as handles for single molecule manipulation. Nucleic Acids Res. 2014, 42, e150, doi: 10.1093/nar/gku760.
81. Suresh, G.; Priyakumar, U.D. Atomistic investigation of the effect of incremental modification of deoxyribose sugars by locked nucleic acid (β-D-LNA and a-L-LNA) moieties on the structures and thermodynamics of DNA-RNA hybrid duplexes. J. Phys. Chem. B 2014, 118, 5853-5863.
82. Wang, G.; Gunic, E.; Girardet, J.L.; Stoisavljevic, V. Conformationally locked nucleosides. Synthesis and hybridization properties of oligodeoxynucleotides containing 2',4'-C-bridged 2'-deoxynucleosides. Bioorg. Med. Chem. Lett. 1999, 9, 1147-1150.
83. Kurreck, J.; Wyszko, E.; Gillen, C.; Erdmann, V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002, 30, 1911-1918.
84. Leech, S.H.; Olie, R.A.; Gautschi, O.; Simoes-Wust, A.P.; Tschopp, S.; Haner, R.; Hall, J.; Stahel, R.A.; Zangemeister-Wittke, U. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int. J. Cancer 2000, 86, 570-576.
85. Astriab-Fisher, A.; Fisher, M.H.; Juliano, R.; Herdewijn, P. Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochem. Pharmacol. 2004, 68, 403-407.
86. Frazier, K.S. Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist's perspective. Toxicol. Pathol. 2015, 43, 78-89.
87. Hair, P.; Cameron, F.; McKeage, K. Mipomersen sodium: First global approval. Drugs 2013, 73, 487-493.
88. Kastelein, J.J.; Wedel, M.K.; Baker, B.F.; Su, J.; Bradley, J.D.; Yu, R.Z.; Chuang, E.; Graham, M.J.; Crooke, R.M. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114, 1729-1735.
89. Raal, F.J.; Santos, R.D.; Blom, D.J.; Marais, A.D.; Charng, M.J.; Cromwell, W.C.; Lachmann, R.H.; Gaudet, D.; Tan, J.L.; Chasan-Taber, S.; et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010, 375, 998-1006.
90. McGowan, M.P.; Tardif, J.C.; Ceska, R.; Burgess, L.J.; Soran, H.; Gouni-Berthold, I.; Wagener, G.; Chasan-Taber, S. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 2012, 7, e49006.
91. Gelsinger, C.; Steinhagen-Thiessen, E.; Kassner, U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs 2012, 72, 1445-1455.
92. Santos, R.D.; Duell, P.B.; East, C.; Guyton, J.R.; Moriarty, P.M.; Chin, W.; Mittleman, R.S. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 2015, 36, 566-575.
93. Sjouke, B.; Balak, D.M.; Beuers, U.; Ratziu, V.; Stroes, E.S. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr. Opin. Lipidol. 2013, 24, 301-306.
94. Flaim, J.D.; Grundy, J.S.; Baker, B.F.; McGowan, M.P.; Kastelein, J.J. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J. Am. Heart Assoc. 2014, 3, e000560, doi: 10.1161/JAHA.113.000560.
95. Song, E.; Lee, S.K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 2003, 9, 347-351.
96. Kim, D.H.; Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8, 173-184.
97. Haynes, M.; Huang, L. Hepatic RNA interference: Delivery by synthetic vectors. Drug Deliv. Transl. Res. 2014, 4, 61-73.
98. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363-366.
99. Wilson, R.C.; Doudna, J.A. Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 2013, 42, 217-239.
100. Knight, S.W.; Bass, B.L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 2001, 293, 2269-2271.
101. Elbashir, S.M.; Lendeckel, W.; Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15, 188-200.
102. Csorba, T.; Lozsa, R.; Hutvagner, G.; Burgyan, J. Polerovirus protein P0 prevents the assembly of small RNA-containing RISC complexes and leads to degradation of ARGONAUTE1. Plant J. 2010, 62, 463-472.
103. Khvorova, A.; Reynolds, A.; Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115, 209-216.
104. Liu, J.; Carmell, M.A.; Rivas, F.V.; Marsden, C.G.; Thomson, J.M.; Song, J.J.; Hammond, S.M.; Joshua-Tor, L.; Hannon, G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305, 1437-1441.
105. Meister, G.; Landthaler, M.; Patkaniowska, A.; Dorsett, Y.; Teng, G.; Tuschl, T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 2004, 15, 185-197.
106. Song, J.J.; Smith, S.K.; Hannon, G.J.; Joshua-Tor, L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004, 305, 1434-1437.
107. Ameres, S.L.; Martinez, J.; Schroeder, R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 2007, 130, 101-112.
108. Cuccato, G.; Polynikis, A.; Siciliano, V.; Graziano, M.; di Bernardo, M.; di Bernardo, D. Modeling RNA interference in mammalian cells. BMC Syst. Biol. 2011, 5, 19, doi: 10.1186/1752-0509-5-19.
109. Hutvagner, G.; Zamore, P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297, 2056-2060.
110. Bartlett, D.W.; Davis, M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006, 34, 322-333.
111. Pan, Q.; Ramakrishnaiah, V.; Henry, S.; Fouraschen, S.; de Ruiter, P.E.; Kwekkeboom, J.; Tilanus, H.W.; Janssen, H.L.; van der Laan, L.J. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012, 61, 1330-1339.
112. Cernilogar, F.M.; Onorati, M.C.; Kothe, G.O.; Burroughs, A.M.; Parsi, K.M.; Breiling, A.; lo Sardo, F.; Saxena, A.; Miyoshi, K.; Siomi, H.; et al. Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila. Nature 2011, 480, 391-395.
113. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6, 686-695.
114. Chiu, Y.L.; Rana, T.M. siRNA function in RNAi: A chemical modification analysis. RNA 2003, 9, 1034-1048.
115. Guga, P.; Koziolkiewicz, M. Phosphorothioate nucleotides and oligonucleotides-Recent progress in synthesis and application. Chem. Biodivers. 2011, 8, 1642-1681.
116. Bramsen, J.B.; Laursen, M.B.; Nielsen, A.F.; Hansen, T.B.; Bus, C.; Langkjaer, N.; Babu, B.R.; Hojland, T.; Abramov, M.; van Aerschot, A.; et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009, 37, 2867-2881.
117. Amarzguioui, M.; Holen, T.; Babaie, E.; Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003, 31, 589-595.
118. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21, 635-637.
119. Fedorov, Y.; Anderson, E.M.; Birmingham, A.; Reynolds, A.; Karpilow, J.; Robinson, K.; Leake, D.; Marshall, W.S.; Khvorova, A. Off-target effects by siRNA can induce toxic phenotype. RNA 2006, 12, 1188-1196.
120. Jackson, A.L.; Burchard, J.; Leake, D.; Reynolds, A.; Schelter, J.; Guo, J.; Johnson, J.M.; Lim, L.; Karpilow, J.; Nichols, K.; et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12, 1197-1205.
121. Sledz, C.A.; Holko, M.; de Veer, M.J.; Silverman, R.H.; Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 2003, 5, 834-839.
122. Marques, J.T.; Williams, B.R. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 2005, 23, 1399-1405.
123. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de Fougerolles, A.; et al. Sequence-specific potent induction of IFN-A by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11, 263-270.
124. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23, 1002-1007.
125. Fitzgerald, K.; Frank-Kamenetsky, M.; Shulga-Morskaya, S.; Liebow, A.; Bettencourt, B.R.; Sutherland, J.E.; Hutabarat, R.M.; Clausen, V.A.; Karsten, V.; Cehelsky, J.; et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383, 60-68.
126. Crooke, S.T.; Graham, M.J.; Zuckerman, J.E.; Brooks, D.; Conklin, B.S.; Cummins, L.L.; Greig, M.J.; Guinosso, C.J.; Kornbrust, D.; Manoharan, M.; et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 1996, 277, 923-937.
127. Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.; Jeffs, L.B.; John, M.; et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441, 111-114.
128. Graham, M.J.; Crooke, S.T.; Monteith, D.K.; Cooper, S.R.; Lemonidis, K.M.; Stecker, K.K.; Martin, M.J.; Crooke, R.M. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 1998, 286, 447-458.
129. Geary, R.S.; Wancewicz, E.; Matson, J.; Pearce, M.; Siwkowski, A.; Swayze, E.; Bennett, F. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem. Pharmacol. 2009, 78, 284-291.
130. Lightfoot, H.L.; Hall, J. Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res. 2012, 40, 10585-10595.
131. Heemskerk, H.; de Winter, C.; van Kuik, P.; Heuvelmans, N.; Sabatelli, P.; Rimessi, P.; Braghetta, P.; van Ommen, G.J.; de Kimpe, S.; Ferlini, A.; et al. Preclinical PK and PD studies on 2'-O-methylphosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 2010, 18, 1210-1217.
132. Watanabe, T.A.; Geary, R.S.; Levin, A.A. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006, 16, 169-180.
133. Gao, X.; Zhao, J.; Han, G.; Zhang, Y.; Dong, X.; Cao, L.; Wang, Q.; Moulton, H.M.; Yin, H. Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol. Ther. 2014, 22, 1333-1341.
134. Geary, R.S. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol. 2009, 5, 381-391.
135. Lee, S.H.; Castagner, B.; Leroux, J.C. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur. J. Pharm. Biopharm. 2013, 85, 5-11.
136. Ming, X. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin. Drug Deliv. 2011, 8, 435-449.
137. Damke, H. Dynamin and receptor-mediated endocytosis. FEBS Lett. 1996, 389, 48-51.
138. Overhoff, M.; Sczakiel, G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep. 2005, 6, 1176-1181.
139. Rydstrom, A.; Deshayes, S.; Konate, K.; Crombez, L.; Padari, K.; Boukhaddaoui, H.; Aldrian, G.; Pooga, M.; Divita, G. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS ONE 2011, 6, e25924, doi: 10.1371/journal.pone.0025924.
140. Turner, J.J.; Jones, S.; Fabani, M.M.; Ivanova, G.; Arzumanov, A.A.; Gait, M.J. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol. Dis. 2007, 38, 1-7.
141. Deshayes, S.; Morris, M.; Heitz, F.; Divita, G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev. 2008, 60, 537-547.
142. Sorensen, D.R.; Leirdal, M.; Sioud, M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003, 327, 761-766.
143. Song, E.; Zhu, P.; Lee, S.K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D.M.; Feng, Y.; Palliser, D.; Weiner, D.B.; Shankar, P.; et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23, 709-717.
144. McNamara, J.O., 2nd.; Andrechek, E.R.; Wang, Y.; Viles, K.D.; Rempel, R.E.; Gilboa, E.; Sullenger, B.A.; Giangrande, P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24, 1005-1015.
145. Koller, E.; Vincent, T.M.; Chappell, A.; De, S.; Manoharan, M.; Bennett, C.F. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011, 39, 4795-4807.
146. Winkler, J. Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 2013, 4, 791-809.
147. Lorenz, P.; Misteli, T.; Baker, B.F.; Bennett, C.F.; Spector, D.L. Nucleocytoplasmic shuttling: A novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 2000, 28, 582-592.
148. Welz, C.; Neuhuber, W.; Schreier, H.; Repp, R.; Rascher, W.; Fahr, A. Nuclear gene targeting using negatively charged liposomes. Int. J. Pharm. 2000, 196, 251-252.
149. Detzer, A.; Overhoff, M.; Wunsche, W.; Rompf, M.; Turner, J.J.; Ivanova, G.D.; Gait, M.J.; Sczakiel, G. Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA 2009, 15, 627-636.
150. Liu, Y.; Franzen, S. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles. Bioconjugate Chem. 2008, 19, 1009-1016.
151. Rozema, D.B.; Lewis, D.L.; Wakefield, D.H.; Wong, S.C.; Klein, J.J.; Roesch, P.L.; Bertin, S.L.; Reppen, T.W.; Chu, Q.; Blokhin, A.V.; et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 12982-12987.
152. Prakash, T.P.; Lima, W.F.; Murray, H.M.; Elbashir, S.; Cantley, W.; Foster, D.; Jayaraman, M.; Chappell, A.E.; Manoharan, M.; Swayze, E.E.; et al. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. ACS Chem. Biol. 2013, 8, 1402-1406.
153. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
154. Dominska, M.; Dykxhoorn, D.M. Breaking down the barriers: SiRNA delivery and endosome escape. J. Cell Sci. 2010, 123, 1183-1189.
155. Alam, M.R.; Ming, X.; Nakagawa, O.; Jin, J.; Juliano, R.L. Covalent conjugation of oligonucleotides with cell-targeting ligands. Bioorg. Med. Chem. 2013, 21, 6217-6223.
156. Oehlke, J.; Birth, P.; Klauschenz, E.; Wiesner, B.; Beyermann, M.; Oksche, A.; Bienert, M. Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Eur. J. Biochem. 2002, 269, 4025-4032.
157. Juliano, R.L. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. Ann. N. Y. Acad. Sci. 2006, 1082, 18-26.
158. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463-478.
159. Kumar, V.; Qin, J.; Jiang, Y.; Duncan, R.G.; Brigham, B.; Fishman, S.; Nair, J.K.; Akinc, A.; Barros, S.A.; Kasperkovitz, P.V. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol. Ther. Nucleic Acids 2014, 3, e210, doi: 10.1038/mtna.2014.61.
160. Wooddell, C.I.; Rozema, D.B.; Hossbach, M.; John, M.; Hamilton, H.L.; Chu, Q.; Hegge, J.O.; Klein, J.J.; Wakefield, D.H.; Oropeza, C.E.; et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 2013, 21, 973-985.
161. Wan, C.; Allen, T.M.; Cullis, P.R. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 2014, 4, 74-83.
162. Avino, A.; Ocampo, S.M.; Lucas, R.; Reina, J.J.; Morales, J.C.; Perales, J.C.; Eritja, R. Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations. Mol. Divers. 2011, 15, 751-757.
163. Nair, J.K.; Willoughby, J.L.; Chan, A.; Charisse, K.; Alam, M.R.; Wang, Q.; Hoekstra, M.; Kandasamy, P.; Kel'in, A.V.; Milstein, S.; et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 2014, 136, 16958-16961.
164. Oishi, M.; Nagasaki, Y.; Itaka, K.; Nishiyama, N.; Kataoka, K. Lactosylated poly(ethylene glycol)- siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 2005, 127, 1624-1625.
165. Weigel, P.H.; Oka, J.A. The surface content of asialoglycoprotein receptors on isolated hepatocytes is reversibly modulated by changes in temperature. J. Biol. Chem. 1983, 258, 5089-5094.
166. Stockert, R.J. The asialoglycoprotein receptor: Relationships between structure, function, and expression. Physiol. Rev. 1995, 75, 591-609.
167. Chen, S.; Tam, Y.Y.; Lin, P.J.; Leung, A.K.; Tam, Y.K.; Cullis, P.R. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J. Control. Release 2014, 196, 106-112.
168. Wong, S.C.; Klein, J.J.; Hamilton, H.L.; Chu, Q.; Frey, C.L.; Trubetskoy, V.S.; Hegge, J.; Wakefield, D.; Rozema, D.B.; Lewis, D.L. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012, 22, 380-390.
169. Nishina, K.; Unno, T.; Uno, Y.; Kubodera, T.; Kanouchi, T.; Mizusawa, H.; Yokota, T. Efficient in vivo delivery of siRNA to the liver by conjugation of a-tocopherol. Mol. Ther. 2008, 16, 734-740.
170. Nishina, T.; Numata, J.; Nishina, K.; Yoshida-Tanaka, K.; Nitta, K.; Piao, W.; Iwata, R.; Ito, S.; Kuwahara, H.; Wada, T.; et al. Chimeric Antisense Oligonucleotide Conjugated to a-Tocopherol. Mol. Ther. Nucleic Acids 2015, 4, e220, doi: 10.1038/mtna.2014.72.
171. Benson, M.D.; Pandey, S.; Witchell, D.; Jazayeri, A.; Siwkowski, A.; Monia, B.; Kluve-Beckerman, B. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2011, 18 (Suppl. S1), 60, doi: 10.3109/13506129.2011.574354021.
172. Benson, M.D.; Kluve-Beckerman, B.; Zeldenrust, S.R.; Siesky, A.M.; Bodenmiller, D.M.; Showalter, A.D.; Sloop, K.W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33, 609-618.
173. Benson, M.D.; Smith, R.A.; Hung, G.; Kluve-Beckerman, B.; Showalter, A.D.; Sloop, K.W.; Monia, B.P. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 2010, 17, 43-49.
174. Benson, M.; Kincaid, J.; Ackermann, E.; Monia, B. A phase 3 study to evaluate ISIS-TTRRx in patients with transthyrethin famial amyloid polyneuropathy (TTR-FAP): Study design and baseline demographics. Neurology 2015, 84, 14 Supplement S50.006.
175. Prakash, T.P.; Graham, M.J.; Yu, J.; Carty, R.; Low, A.; Chappell, A.; Schmidt, K.; Zhao, C.; Aghajan, M.; Murray, H.F.; et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014, 42, 8796-8807.
176. Ackermann, E.J.; Guo, S.; Booten, S.; Alvarado, L.; Benson, M.; Hughes, S.; Monia, B.P. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012, 19 (Suppl. S1), 43-44.
177. Zemany, L.; Bhanot, S.; Peroni, O.D.; Murray, S.F.; Moraes-Vieira, P.M.; Castoldi, A.; Manchem, P.; Guo, S.; Monia, B.P.; Kahn, B.B. Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice. Diabetes 2015, 64, 1603-1614.
178. Coelho, T.; Adams, D.; Silva, A.; Lozeron, P.; Hawkins, P.N.; Mant, T.; Perez, J.; Chiesa, J.; Warrington, S.; Tranter, E.; et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369, 819-829.
179. Suhr, O.B.; Coelho, T.; Buades, J.; Pouget, J.; Conceicao, I.; Berk, J.; Schmidt, H.; Waddington-Cruz, M.; Campistol, J.M.; Bettencourt, B.R.; et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet J. Rare Dis. 2015, 10, 109, doi: 10.1186/s13023-015-0326-6.
180. Sohlenius-Sternbeck, A.K. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol. In Vitro 2006, 20, 1582-1586.
181. Forbes, D.C.; Peppas, N.A. Oral delivery of small RNA and DNA. J. Control. Release 2012, 162, 438-445.